Endometriosis Management: Workflow on Genomics and Proteomics and Future Biomolecular Pharmacotherapy

Author(s): Andrea Tinelli, Roberta Martignago, Daniele Vergara, Giuseppe Leo, Antonio Malvasi, Raffaele Tinelli

Journal Name: Current Medicinal Chemistry

Volume 15 , Issue 21 , 2008

Become EABM
Become Reviewer
Call for Editor


Background: Endometriosis is an estrogen-dependent disease, associated with pelvic pain and infertility, with still limited knowledge of the pathogenesis, pathophysiology of related infertility and evolution. Objective: To investigate proteogenomic approaches and new trends of endometriosis treatment. Methods: A literature search was carried out for all articles on endometriosis related to immune system, and to nonhormonal, antiangiogenic and experimental therapies. Results/Conclusions: Classic endometriosis pharmacotherapy is represented by GnRH agonists, oral contraceptives and Type II progesterone receptor ligands. New proteomic and genomic technologies could help to clarify the aetiology of endometriosis and promise the rapid identification of a new generation of drugs with a specific molecular target, with the aim to ameliorate the patients quality of life.

Keywords: Endometriosis, genomics, proteomics, GnRH agonists, angiogenesis, aromatase inhibitors, immune system, nonhormonal treatments, genetical predisposition

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [2099 - 2107]
Pages: 9
DOI: 10.2174/092986708785747571
Price: $65

Article Metrics

PDF: 9